Brand New Drugs

⚠️ These drugs are still being tested. They are not yet approved and may not work as hoped. This is early science, not medical advice.

What This Page Is About

Scientists find new drugs all the time. Some of them might help people live longer, healthier lives. On this page, we track the newest ones — the drugs that are just showing up in the news, in early tests, and in biotech reports like Seeking Alpha.

Think of this as your early warning system. Before a drug makes headlines, before your doctor knows about it, you will see it here.

How To Use This Page

Every drug we cover gets its own page. We explain:

What it does — in plain English, no big words
Who it might help — what condition or problem it targets
Where it stands — is it in early tests? Bigger trials? Almost ready?
What we do not know yet — the risks and open questions

Why Track New Drugs?

Because the drugs that will matter most to your health ten years from now are being discovered today. Knowing about them early gives you time to learn, ask questions, and make smart choices.

Drugs We Are Tracking

🥇 Enlicitide (MK-0616)

A once-daily pill that lowers LDL cholesterol as powerfully as injectable PCSK9 inhibitors — currently in Phase 3 trials.

🥇 ER-100

A first-in-class drug for age-related eye disease that showed vision improvement in Phase 2 trials.

🥉 STX-1150

A one-shot CRISPR gene-silencing therapy designed to lower cholesterol for years after a single dose — just entered first human trials.

🥈 Ontunisertib (RV-1201)

A selective AAK1 inhibitor entering Phase 2 trials — targets neuropathic pain at its source.

🥇 Petrelintide (ZP8396)

Zealand Pharma's long-acting amylin analog — Phase 2 data shows durable weight loss with better tolerability than GLP-1s.

🥇 REVTORPYK (gedatolisib)

Celcuity's dual PI3K/mTOR inhibitor — FDA approved for advanced breast cancer, with label expansion expected Q3 2026.

🥈 LYTENAVA (bevacizumab-vikg)

First FDA-approved ophthalmic bevacizumab for wet AMD — the leading cause of blindness in older adults.

🥈 NVG-291

First-in-class peptide that releases your body's natural nerve repair brakes — positive Phase 2 data in spinal cord injury.

🥇 Tinlarebant

First oral pill for retinal degeneration — Belite Bio's RBP4 antagonist slows vision loss in Stargardt disease, with dry AMD studies underway. NDA under FDA review.

🥇 ORZEYFUL (Oveporexton)

First-in-class orexin receptor agonist — replaces the missing brain chemical in narcolepsy type 1. FDA approved August 2026. Opens the door to orexin-based drugs for age-related sleep decline.

🥇 Rusfertide

First-in-class hepcidin mimetic — a once-weekly shot that could replace old-fashioned blood draws for polycythemia vera. Awaiting FDA approval.